Shanghai Obio Technology (Group) (688238) Stock Overview
A biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
688238 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Shanghai Obio Technology (Group) Corp., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.90 |
| 52 Week High | CN¥9.20 |
| 52 Week Low | CN¥4.49 |
| Beta | 0.60 |
| 1 Month Change | 12.06% |
| 3 Month Change | 14.00% |
| 1 Year Change | 43.90% |
| 3 Year Change | -47.82% |
| 5 Year Change | n/a |
| Change since IPO | -53.13% |
Recent News & Updates
Recent updates
Why Investors Shouldn't Be Surprised By Obio Technology (Shanghai) Corp., Ltd.'s (SHSE:688238) 27% Share Price Surge
Feb 21
After Leaping 26% Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) Shares Are Not Flying Under The Radar
Nov 15Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) Looks Just Right With A 27% Price Jump
Oct 01Some Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 21Subdued Growth No Barrier To Obio Technology (Shanghai) Corp., Ltd. (SHSE:688238) With Shares Advancing 30%
Mar 06Shareholder Returns
| 688238 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 14.8% | -4.6% | -2.9% |
| 1Y | 43.9% | 23.1% | 25.0% |
Return vs Industry: 688238 exceeded the CN Life Sciences industry which returned 23.1% over the past year.
Return vs Market: 688238 exceeded the CN Market which returned 25% over the past year.
Price Volatility
| 688238 volatility | |
|---|---|
| 688238 Average Weekly Movement | 5.2% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 3.2% |
Stable Share Price: 688238 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688238's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 678 | Oudong Pan | www.obiosh.com |
Shanghai Obio Technology (Group) Corp., Ltd., a biotechnology company, engages in the provision of technical services for the field of regenerative medicine and anti-aging in China. The company offers customized plasmid design and viral vector packaging services; AAV serotypes and tissue-specific promoters to support scientific research; and research grade, NHP Grade, cGMP grade vector manufacturing process, for basic research, translational research and clinical trials. It also provides CDMO services encompassing process development, analytical methods, IND-enabling chemistry, manufacturing, and controls; and clinical and commercial manufacturing for viral vector, oncolytic virus, and cell therapy products.
Shanghai Obio Technology (Group) Corp., Ltd. Fundamentals Summary
| 688238 fundamental statistics | |
|---|---|
| Market cap | CN¥4.98b |
| Earnings (TTM) | -CN¥220.72m |
| Revenue (TTM) | CN¥267.66m |
Is 688238 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688238 income statement (TTM) | |
|---|---|
| Revenue | CN¥267.66m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥267.66m |
| Other Expenses | CN¥488.38m |
| Earnings | -CN¥220.72m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
Apr 21, 2026
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | -82.46% |
| Debt/Equity Ratio | 26.1% |
How did 688238 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/10 20:22 |
| End of Day Share Price | 2026/03/10 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shanghai Obio Technology (Group) Corp., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wanhua Wu | China International Capital Corporation Limited |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |